<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609167</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000583225</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0686</secondary_id>
    <secondary_id>06-002613</secondary_id>
    <secondary_id>NCI-2010-02147</secondary_id>
    <nct_id>NCT00609167</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>A Phase II Trial of Cyclophosphamide, Bortezomib and Dexamethasone (CYBOR-D) in Patients With Newly Diagnosed Active Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the
      enzymes needed for cell growth. Giving cyclophosphamide and dexamethasone together with
      bortezomib may kill more cancer cells.

      PURPOSE: This phase II trial is studying giving cyclophosphamide and dexamethasone together
      with bortezomib to see how well it works in treating patients with newly diagnosed multiple
      myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

      * To evaluate the response rate (complete response [CR], near CR [nCR], and very good partial
      response) in patients with newly diagnosed multiple myeloma treated with bortezomib in
      combination with cyclophosphamide and dexamethasone .

      Secondary

        -  Determine the overall response rate (partial response, PR, or better) in these patients
           after 4, 8, and 12 courses of this regimen.

        -  Determine the duration of progression-free and overall survival of patients treated with
           this regimen.

        -  To evaluate the toxicity of this regimen in these patients.

        -  To evaluate the ability to successfully collect peripheral blood stem cells from these
           patients after 4 months of this regimen.

        -  To evaluate the CR or nCR rate in these patients after 8 and 12 courses of this regimen.

      OUTLINE: This is a multicenter study.

      Patients receive oral cyclophosphamide on days 1, 8, 15, and 22; bortezomib IV on days 1, 4,
      8 , and 11 OR days 1, 8, 15 and 22; and dexamethasone on days 1-4, 9-12, and 17-20 in courses
      1 and 2 and days 1, 18, 15, and 22 in all subsequent courses. Courses repeats every 28 days
      for up to 12 courses in the absence of disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment</measure>
    <time_frame>After 4 months of treatment</time_frame>
    <description>Response that was confirmed on 2 consecutive evaluations during the first 4 months of treatment.
Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
near Complete Response (nCR): Patients who meet all criteria for CR except a positive immunofixation will be classified as nCR.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;100mg per 24hours; &lt;=5% plasma cells in bone marrow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>PFS was defined as the time from registration to progression or death due to any cause.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl)
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)
Definite development of new bone lesion or soft tissue plasmacytomas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of registration until death (up to 5 years)</time_frame>
    <description>OS was defined as the time from registration to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles</measure>
    <time_frame>4 cycles</time_frame>
    <description>Response that was confirmed on 2 consecutive evaluations after 8 months of treatment.
CR, nCR and VGPR as defined in the primary outcome.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or
Urine M-Component &gt;=90% reduction or &lt;200mg per 24hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Duration of study (up to 12 cycles)</time_frame>
    <description>Duration of response was calculated from the documentation (date) of first response (CR, nCR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 8 Cycles</measure>
    <time_frame>After 8 cycles of treatment</time_frame>
    <description>Response that was confirmed on 2 consecutive evaluations after 8 cycles of treatment.
Criteria for CR, nCR, VGPR and PR are defined in prior outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles</measure>
    <time_frame>After 12 cycles of treatment</time_frame>
    <description>Response that was confirmed on 2 consecutive evaluations after 12 cycles of treatment.
Criteria for CR, nCR, VGPR and PR are defined in prior outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Adverse Events</measure>
    <time_frame>Every cycle during treatment (up to 12 cycles)</time_frame>
    <description>Severe adverse events were defined as grade 3 or higher, regardless of attribution to study drugs. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant</measure>
    <time_frame>After 4 cycles of treatment</time_frame>
    <description>Evaluation of the ability to successfully collect peripheral blood stem cells following four months (cycles) of combination therapy.</description>
  </secondary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>First 33 patients: 1.3 mg/m^2 IV Days 1, 4, 8 &amp; 11
Remaining 30 patients: 1.5 mg/m^2 IV Days 1, 8, 15 &amp; 22</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>300mg/m^2 PO days 1, 8, 15 &amp; 22</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20
Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Confirmed diagnosis of symptomatic multiple myeloma

               -  Durie Salmon stage 2 or higher

               -  Previously untreated multiple myeloma (including immunomodulatory drugs such as
                  thalidomide) with the exception of bisphosphonates

          -  Evaluable or measurable disease, as defined by at least one of the following:

               -  Serum monoclonal protein ≥ 1 g/dL (measurable disease)

               -  Urine monoclonal protein ≥ 200 mg/24 hours by protein electrophoresis (measurable
                  disease)

               -  Serum-free light chains (FLC) ≥ 10 mg/dL, kappa or lambda, accompanied by an
                  abnormal kappa/lambda ratio

        Serum FLC's should only be used for patients without measurable serum or urine m-spike

        - Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)

        * Patients diagnosed with smoldering myeloma or monoclonal gammopathy of undetermined
        significance are not eligible

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2

             - ECOG PS of 3 will be allowed if secondary to pain in the opinion of the Investigator

          -  Total bilirubin normal OR direct bilirubin ≤ 2.0 mg/dL

          -  Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)

          -  AST ≤ 3 times ULN

          -  Creatinine ≤ 3.5 mg/dL

          -  Absolute neutrophil count ≥ 1,000/mm³ without transfusion or growth factor

          -  Platelet count ≥ 100,000/mm³ without transfusion or growth factor

          -  Willingness and the physical and mental capability to provide written informed consent

          -  Willingness to return to Mayo Clinic Arizona/Princess Margaret Hospital for follow-up

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Peripheral sensory neuropathy ≥ grade 2 as defined by National Cancer Institute (NCI)
             Common Terminology for Common Adverse Events (CTCAE) version 3.0

          -  Known hypersensitivity to compounds containing boron or mannitol

          -  Active uncontrolled infection

          -  Severe cardiac comorbidity including but not limited to:

               -  New York Heart Association class III or IV heart failure

               -  History of myocardial infarction within the past 6 months

               -  Uncontrolled angina or electrocardiographic (ECG) evidence of acute ischemia

               -  Severe uncontrolled ventricular arrhythmias or ECG evidence of active conduction
                  system abnormalities

               -  Cardiac amyloidosis with hypotension (i.e., systolic blood pressure &lt; 100 mm Hg)

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent study compliance or completion of study treatment

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior high-dose corticosteroid therapy for 12 days or less is permitted for emergent
             complications from newly diagnosed multiple myeloma

          -  More than 14 days since prior investigational agents

          -  No concurrent steroids or any other anticancer agents or treatments

             - Patients may receive the equivalent of up to 20 mg prednisone per day for concurrent
             illness or adrenal replacement therapy

          -  Concurrent palliative radiotherapy for bony pain or fracture is allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Keith Stewart, M.B., Ch.B.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009 Jul;23(7):1337-41. doi: 10.1038/leu.2009.26. Epub 2009 Feb 19.</citation>
    <PMID>19225538</PMID>
  </results_reference>
  <results_reference>
    <citation>Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, Hentz J, Pirooz NA, Piza JG, Tiedemann R, Mikhael JR, Bergsagel PL, Leis JF, Fonseca R, Stewart AK. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010 Apr 22;115(16):3416-7. doi: 10.1182/blood-2010-02-271676.</citation>
    <PMID>20413666</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>November 5, 2010</results_first_submitted>
  <results_first_submitted_qc>November 5, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2010</results_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alexander Keith Stewart, M.B.Ch.B</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty-three(63) participants were recruited between December 2006 and October 2008 at either Mayo Clinic Arizona or Princess Margaret Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
          <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
        </group>
        <group group_id="P2">
          <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
          <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stem Cell Transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
          <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
        </group>
        <group group_id="B2">
          <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
          <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="38" upper_limit="75"/>
                    <measurement group_id="B2" value="61" lower_limit="36" upper_limit="70"/>
                    <measurement group_id="B3" value="61" lower_limit="36" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parameters of Hematologic Response - Serum M-spike &gt;=1g/dL</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parameter of Hematologic Response - Serum Immunoglobulin Free Light Chain &gt;=10mg/dL</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parameter of Hematologic Response - Urine M-Spike &gt;= 200mg/24 hours</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parameter of Hematologic Response - Bone Marrow Plasma Cells &gt; 30%</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment</title>
        <description>Response that was confirmed on 2 consecutive evaluations during the first 4 months of treatment.
Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
near Complete Response (nCR): Patients who meet all criteria for CR except a positive immunofixation will be classified as nCR.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;100mg per 24hours; &lt;=5% plasma cells in bone marrow.</description>
        <time_frame>After 4 months of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment</title>
          <description>Response that was confirmed on 2 consecutive evaluations during the first 4 months of treatment.
Complete Response(CR): Complete disappearance of M-protein from serum and urine on immunofixation, normalization of Free Light Chain (FLC) ratio and &lt;5% plasma cells in bone marrow.
near Complete Response (nCR): Patients who meet all criteria for CR except a positive immunofixation will be classified as nCR.
Very Good Partial Response(VGPR): &gt;=90% reduction in serum M-component; Urine M-Component &lt;100mg per 24hours; &lt;=5% plasma cells in bone marrow.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time from registration to progression or death due to any cause.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl)
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)
Definite development of new bone lesion or soft tissue plasmacytomas</description>
        <time_frame>up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time from registration to progression or death due to any cause.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl)
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)
Definite development of new bone lesion or soft tissue plasmacytomas</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median PFS for group 1 has not been attained.</measurement>
                    <measurement group_id="O2" value="NA">The median PFS for group 2 has not been attained</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from registration to death of any cause.</description>
        <time_frame>From date of registration until death (up to 5 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from registration to death of any cause.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median OS for group 1 has not been attained.</measurement>
                    <measurement group_id="O2" value="NA">Median OS for group 2 has not been attained.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles</title>
        <description>Response that was confirmed on 2 consecutive evaluations after 8 months of treatment.
CR, nCR and VGPR as defined in the primary outcome.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or
Urine M-Component &gt;=90% reduction or &lt;200mg per 24hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
        <time_frame>4 cycles</time_frame>
        <population>Participants who received 4 cycles of treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles</title>
          <description>Response that was confirmed on 2 consecutive evaluations after 8 months of treatment.
CR, nCR and VGPR as defined in the primary outcome.
Partial Response(PR): &gt;=50% reduction in serum M-component and/or
Urine M-Component &gt;=90% reduction or &lt;200mg per 24hours; or &gt;=50% decrease in difference between involved and uninvolved FLC levels.</description>
          <population>Participants who received 4 cycles of treatment were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response was calculated from the documentation (date) of first response (CR, nCR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded.</description>
        <time_frame>Duration of study (up to 12 cycles)</time_frame>
        <population>Participants who achieved a partial response(PR) or better were evaluable for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response was calculated from the documentation (date) of first response (CR, nCR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded.</description>
          <population>Participants who achieved a partial response(PR) or better were evaluable for this analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median duration of response for group 1 was not attained.</measurement>
                    <measurement group_id="O2" value="NA">Median duration of response for group 2 was not attained.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 8 Cycles</title>
        <description>Response that was confirmed on 2 consecutive evaluations after 8 cycles of treatment.
Criteria for CR, nCR, VGPR and PR are defined in prior outcomes.</description>
        <time_frame>After 8 cycles of treatment</time_frame>
        <population>Participants who received 8 cycles of treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 8 Cycles</title>
          <description>Response that was confirmed on 2 consecutive evaluations after 8 cycles of treatment.
Criteria for CR, nCR, VGPR and PR are defined in prior outcomes.</description>
          <population>Participants who received 8 cycles of treatment were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles</title>
        <description>Response that was confirmed on 2 consecutive evaluations after 12 cycles of treatment.
Criteria for CR, nCR, VGPR and PR are defined in prior outcomes.</description>
        <time_frame>After 12 cycles of treatment</time_frame>
        <population>No participants received 12 cycles of treatment; therefore, all participants are non-evalualble.</population>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles</title>
          <description>Response that was confirmed on 2 consecutive evaluations after 12 cycles of treatment.
Criteria for CR, nCR, VGPR and PR are defined in prior outcomes.</description>
          <population>No participants received 12 cycles of treatment; therefore, all participants are non-evalualble.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Adverse Events</title>
        <description>Severe adverse events were defined as grade 3 or higher, regardless of attribution to study drugs. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.</description>
        <time_frame>Every cycle during treatment (up to 12 cycles)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Adverse Events</title>
          <description>Severe adverse events were defined as grade 3 or higher, regardless of attribution to study drugs. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant</title>
        <description>Evaluation of the ability to successfully collect peripheral blood stem cells following four months (cycles) of combination therapy.</description>
        <time_frame>After 4 cycles of treatment</time_frame>
        <population>At the time of publication, data was available on 18 patients for group 2.</population>
        <group_list>
          <group group_id="O1">
            <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
            <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
          </group>
          <group group_id="O2">
            <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
            <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22
Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22
Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant</title>
          <description>Evaluation of the ability to successfully collect peripheral blood stem cells following four months (cycles) of combination therapy.</description>
          <population>At the time of publication, data was available on 18 patients for group 2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CyBorD (Bortezomib 1.3mg/m^2)</title>
          <description>Bortezomib 1.3mg/m^2 by IV days 1, 4, 8 &amp; 11 Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22 Dexamethasone 40mg PO days 1-4, 9-12, 17-20</description>
        </group>
        <group group_id="E2">
          <title>CyBorD (Bortezomib 1.5mg/m^2)</title>
          <description>Bortezomib 1.5mg/m^2 by IV days 1, 8, 15 &amp; 22 Cyclophosphamide 300mg/m^2 PO days 1, 8, 15 &amp; 22 Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 &amp; 22</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Blood Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lung (pneumonia) infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemia/Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="52" subjects_affected="18" subjects_at_risk="33"/>
                <counts group_id="E2" events="75" subjects_affected="24" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Conjunctiva infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper airway infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="68" subjects_affected="27" subjects_at_risk="33"/>
                <counts group_id="E2" events="28" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="52" subjects_affected="21" subjects_at_risk="33"/>
                <counts group_id="E2" events="64" subjects_affected="17" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Taste</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Euphoria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. A. Keith Stewart</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>stewart.keith@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

